- Home
- IFRX vs AVTX Comparison
IFRX vs AVTX Comparison
Compare IFRX & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- AVTX
- Stock Information
- Founded
- IFRX 2007
- AVTX 2011
- Country
- IFRX Germany
- AVTX United States
- Employees
- IFRX N/A
- AVTX N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- IFRX Health Care
- AVTX Health Care
- Exchange
- IFRX Nasdaq
- AVTX Nasdaq
- Market Cap
- IFRX 53.5M
- AVTX 57.4M
- IPO Year
- IFRX 2017
- AVTX 2015
- Fundamental
- Price
- IFRX $0.85
- AVTX $4.80
- Analyst Decision
- IFRX Strong Buy
- AVTX Strong Buy
- Analyst Count
- IFRX 4
- AVTX 7
- Target Price
- IFRX $7.75
- AVTX $31.00
- AVG Volume (30 Days)
- IFRX 371.5K
- AVTX 81.3K
- Earning Date
- IFRX 08-07-2025
- AVTX 08-11-2025
- Dividend Yield
- IFRX N/A
- AVTX N/A
- EPS Growth
- IFRX N/A
- AVTX N/A
- EPS
- IFRX N/A
- AVTX N/A
- Revenue
- IFRX $140,242.00
- AVTX $441,000.00
- Revenue This Year
- IFRX N/A
- AVTX N/A
- Revenue Next Year
- IFRX $6,309.47
- AVTX N/A
- P/E Ratio
- IFRX N/A
- AVTX N/A
- Revenue Growth
- IFRX 30.90
- AVTX N/A
- 52 Week Low
- IFRX $0.71
- AVTX $3.39
- 52 Week High
- IFRX $2.82
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- IFRX 45.30
- AVTX 51.53
- Support Level
- IFRX $0.78
- AVTX $4.61
- Resistance Level
- IFRX $0.93
- AVTX $5.02
- Average True Range (ATR)
- IFRX 0.05
- AVTX 0.26
- MACD
- IFRX 0.03
- AVTX -0.02
- Stochastic Oscillator
- IFRX 42.32
- AVTX 54.55
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).